1
Darrell R Anderson, Nabil Hanna, John E Leonard, Roland A Newman, Mitchell E Reff, William H Rastetter: Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma. Idec Pharmaceuticals Corporation, Burns Doane Swecker & Mathis, April 7, 1998: US05736137 (387 worldwide citation)

Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chimeric anti-CD20 antibodies, radiolabeled anti-CD20 antibodies, an ...


2
Darrell R Anderson, Nabil Hanna, John E Leonard, Roland A Newman, Mitchell E Reff, William H Rastetter: Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma. IDEC Pharmaceuticals Corporation, Burns Doane Swecker & Mathis, July 7, 1998: US05776456 (187 worldwide citation)

Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chimeric anti-CD20 antibodies, radiolabeled anti-CD20 antibodies, an ...


3
Darrell R Anderson, Nabil Hanna, John E Leonard, Roland A Newman, Mitchell E Reff, William H Rastetter: Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma. Burns Doane Swecker & Mathis, December 1, 1998: US05843439 (100 worldwide citation)

Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chimeric anti-CD20 antibodies, radiolabeled anti-CD20 antibodies, an ...


4
Darrell R Anderson, Nabil Hanna, Roland A Newman, Mitchell E Reff, William H Rastetter: Chimeric and radiolabelled antibodies specific to human CD20 antigen and use thereof for treatment of B-cell lymphoma. IDEC Pharmaceutical Corporation, Robin L Teskin, June 4, 2002: US06399061 (86 worldwide citation)

Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chimeric anti-CD20 antibodies, radiolabeled anti-CD20 antibodies, an ...


5
Darrell R Anderson, Nabil Hanna, Roland A Newman, Mitchell E Reff, William H Rastetter: Anti-CD20 antibodies. Biogen Idec, Sidley Austin, September 9, 2008: US07422739 (83 worldwide citation)

Disclosed are chimeric, immunologically active, isolated, and radiolabeled antibodies directed against the CD20 antigen. The antibodies are useful for treating and diagnosing B cell disorders.


6
Mitchell E Reff: Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same. IDEC Pharmaceutical Corporation, Burns Doane Swecker & Mathis L, December 12, 2000: US06159730 (37 worldwide citation)

Disclosed herein are fully impaired consensus Kozak sequences which are most typically used with dominant selectable markers of transcriptional cassettes which are a part of an expression vector. These vectors are most typically utilized in the expression of proteins in mammalian expression systems. ...


7
Darrell R Anderson, Nabil Hanna, John E Leonard, Roland A Newman, Mitchell E Reff, William H Rastetter: Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma. IDEC Pharmaceuticals Corporation, Robin L Teskin, Pillsbury Winthrop, January 27, 2004: US06682734 (35 worldwide citation)

Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chimeric anti-CD20 antibodies, radiolabeled anti-CD20 antibodies, an ...


8
Mitchell E Reff: Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same. IDEC Pharmaceuticals Corporation, Burns Doane Swecker & Mathis L, March 31, 1998: US05733779 (30 worldwide citation)

Disclosed herein are fully impaired consensus Kozak sequences which are most typically used with dominant selectable markers of transcriptional cassettes which are a part of an expression vector. These vectors are most typically utilized in the expression of proteins in mammalian expression systems. ...


9
Mitchell E Reff: Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same. IDEC Pharmaceuticals Corporation, Burns Doane Swecker & Mathis L, July 15, 1997: US05648267 (29 worldwide citation)

Disclosed herein are fully impaired consensus Kozak sequences which are most typically used with dominant selectable markers of transcriptional cassettes which are a part of an expression vector. These vectors are most typically utilized in the expression of proteins in mammalian expression systems. ...


10
Mitchell E Reff, William S Kloetzer, Takehiko Nakamura: Gamma-1 anti-human CD23 monoclonal antibodies. IDEC Pharmaceuticals Corporation, Seikagaku Corporation, Burns Doane Swecker & Mathis, January 4, 2000: US06011138 (28 worldwide citation)

Anti-human CD23 monoclonal antibodies containing human gamma 1 constant domains and therapeutic uses are provided. These antibodies inhibit IL-4 induced IgE production by B-cells significantly greater than antibodies containing other constant domains.